NCT05162027 - Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 26, 2022

Primary Completion Date

January 3, 2023

Study Completion Date

January 3, 2023

Conditions

Temporomandibular Disorders

Interventions

DRUG

Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe

Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.

DRUG

Placebo

Administered once every 4 weeks/28 days at visit 1, visit 2 and visit 3 for a total of 3 cycles.

Trial Locations (1)

University of Maryland, School of Dentistry, Brotman Facial Pain Clinic, Baltimore